Eterna Therapeutics ERNA 深 滬
等待開盤 09-24 09:30:00 美东时间
3.65
-0.150
-3.95%
華盛通- 最 高3.79
- 今 開3.73
- 成交量 6237股
- 最 低 3.65
- 昨 收 3.80
- 總市值 595.83万
- 52周最高 71.4975
- 市盈率 靜 --
- 換手率 0.38%
- 52周最低 3.1829
- 委 比 -99.87%
- 總股本 163.24万
- 歷史最高 4762500.00
- 量 比 0.34
- 振 幅 3.68%
- 歷史最低 3.355
- 每 手 1
- 風險率 13.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eterna Therapeutics Updates Investors With New Corporate Materials
Eterna Therapeutics ( ($ERNA) ) has provided an announcement. On September 16, ...
09-17 05:57
Eterna Therapeutics appoints independent director Robert J. Spiegel
Eterna Therapeutics ( ($ERNA) ) has issued an update. On September 14, 2026, Er...
09-17 05:18
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in comb...
07-15 19:53
Eterna Therapeutics announces finance leadership transition and search
An update from Eterna Therapeutics ( ($ERNA) ) is now available. On June 22, 20...
06-27 05:09
Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progress across manufacturing, regulatory and clinical development activities supporting ERNA-101, the Company's lead on...
06-17 20:47
Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study Initiation
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the development of ERNA-101,
05-27 20:13
Ernexa Stock Is Jumping Today: What's Going On?
Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA‑101 in ovarian cancer.
05-13 03:22
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Agilon Health (NYSE:AGL) shares moved upwards by 115.7% to $60.08 duri...
05-08 01:05
Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data
Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade.
05-06 22:52
